Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1990 2
1992 2
1993 2
1994 1
1995 1
1996 1
1997 4
1999 1
2001 3
2003 2
2005 2
2006 1
2008 2
2009 2
2010 3
2011 2
2013 4
2014 3
2015 5
2016 5
2017 5
2018 2
2019 3
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs.
Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy-Hulbert A, Adams RH, Sheppard D. Henderson NC, et al. Among authors: prinsen mj. Nat Med. 2013 Dec;19(12):1617-24. doi: 10.1038/nm.3282. Epub 2013 Nov 10. Nat Med. 2013. PMID: 24216753 Free PMC article.
Eye irritation.
Eskes C, Bessou S, Bruner L, Curren R, Harbell J, Jones P, Kreiling R, Liebsch M, McNamee P, Pape W, Prinsen MK, Seidle T, Vanparys P, Worth A, Zuang V. Eskes C, et al. Among authors: prinsen mk. Altern Lab Anim. 2005 Jul;33 Suppl 1:47-81. doi: 10.1177/026119290503301s09. Altern Lab Anim. 2005. PMID: 16194141 No abstract available.
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
Grobben Y, de Man J, van Doornmalen AM, Muller M, Willemsen-Seegers N, Vu-Pham D, Mulder WR, Prinsen MBW, de Wit J, Sterrenburg JG, van Cauter F, den Ouden JE, van Altena AM, Massuger LF, Uitdehaag JCM, Buijsman RC, Zaman GJR. Grobben Y, et al. Among authors: prinsen mbw. Front Immunol. 2021 Jan 28;11:609490. doi: 10.3389/fimmu.2020.609490. eCollection 2020. Front Immunol. 2021. PMID: 33584686 Free PMC article.
A proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom-Up and Top-Down approaches.
Scott L, Eskes C, Hoffmann S, Adriaens E, Alepée N, Bufo M, Clothier R, Facchini D, Faller C, Guest R, Harbell J, Hartung T, Kamp H, Varlet BL, Meloni M, McNamee P, Osborne R, Pape W, Pfannenbecker U, Prinsen M, Seaman C, Spielmann H, Stokes W, Trouba K, Berghe CV, Goethem FV, Vassallo M, Vinardell P, Zuang V. Scott L, et al. Among authors: prinsen m. Toxicol In Vitro. 2010 Feb;24(1):1-9. doi: 10.1016/j.tiv.2009.05.019. Epub 2009 May 31. Toxicol In Vitro. 2010. PMID: 19490935 Review.
Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells.
Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Gao F, Eissenberg LG, Heier RF, Arnett SD, Meyers MJ, Prinsen MJ, Griggs DW, Trumpp A, Ruminski PG, Morrow DM, Bonig HB, Link DC, DiPersio JF. Karpova D, et al. Among authors: prinsen mj. J Clin Invest. 2019 May 14;129(7):2745-2759. doi: 10.1172/JCI124738. J Clin Invest. 2019. PMID: 31085833 Free PMC article.
TTK Inhibitors as a Targeted Therapy for CTNNB1 (β-catenin) Mutant Cancers.
Zaman GJR, de Roos JADM, Libouban MAA, Prinsen MBW, de Man J, Buijsman RC, Uitdehaag JCM. Zaman GJR, et al. Among authors: prinsen mbw. Mol Cancer Ther. 2017 Nov;16(11):2609-2617. doi: 10.1158/1535-7163.MCT-17-0342. Epub 2017 Jul 27. Mol Cancer Ther. 2017. PMID: 28751540
56 results